# Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma

> **NCT07691515** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Zhejiang Cancer Hospital** · enrollment: 140 (estimated)

## Conditions studied

- Intrahepatic Cholangiocarcinoma (Icc)

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **DRUG:** Tislelizumab
- **DRUG:** Lenvatinib
- **PROCEDURE:** Transcatheter Arterial Chemoembolization
- **PROCEDURE:** Hepatic Arterial Infusion Chemotherapy

## Key facts

- **NCT ID:** NCT07691515
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2030-01
- **Final completion:** 2030-07
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07691515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07691515, "Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07691515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*